Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis division...

    Novartis division Alcon spinoff ousts Baer from Swiss benchmark SMI

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-04-05T09:00:03+05:30  |  Updated On 16 Aug 2021 5:35 PM IST

    Novartis has estimated Alcon's value at around 25 billion Swiss francs ($25 billion), while some analysts predict an initial market capitalisation of 21 billion francs ($21 billion) to 23 billion, implying shares worth from 43 to 47 francs.


    ZURICH: Novartis's spinoff of its eye care division Alcon, set for Tuesday, April 9, marks the largest Swiss stock deal in a decade and forces a reshuffle of the benchmark Swiss Market Index (SMI) as private bank Julius Baer gets booted out.


    Novartis has estimated Alcon's value at around 25 billion Swiss francs ($25 billion), while some analysts predict an initial market capitalisation of 21 billion francs ($21 billion) to 23 billion, implying shares worth from 43 to 47 francs.


    Read Also: Novartis division resubmits USFDA application for biosimilar Pegfilgrastim


    By contrast, Baer's value has tumbled by a third in a year to 9.3 billion francs. It will instead be included in the SMIM index, replacing Aryzta, SIX Swiss Exchange said after Tuesday's market close.


    Dominated by Nestle, Novartis and Roche, the SMI is Switzerland's most important index. Membership is based on market capitalisation, adjusted for the free float of readily tradable shares in its constituents.


    Alcon is being spun off in a one-for-five share deal announced by Novartis last June as it focuses on new drugs rather than the surgical devices and contact lenses Alcon makes.


    Read Also: Novartis to face lawsuit over doctor kickbacks


    Joining the SMI may boost demand from funds focusing on the top Swiss companies. Yet Alcon's inclusion means healthcare and medical technology will weigh even more heavily on the SMI.


    Novartis's weighting had been capped 18 per cent, but with Alcon, the two will account for up to 21.5 per cent of the SMI, Zuercher Kantonalbank analysts estimated on Wednesday.


    Novartis's biggest owners - BlackRock, the Sandoz family, Capital Research Global Investors and Vanguard Group - will have similar holdings in Alcon, between 2.5 per cent and 4.5 per cent.


    "We anticipate incremental buying of Alcon shares by some funds seeking to build a full-size position, offset by others not wanting to own a non-pharma eyecare company," Jefferies analyst Peter Welford said.


    Novartis bought Alcon's eye surgery and contact lens portfolio in stages through 2010 for $52 billion from Nestle, only to see it lose ground to competitors as sales and profitability slipped.


    Read Also: Novartis to pay $310 million for assets from inflammation specialist IFM


    In surgical equipment, Alcon competes against Johnson & Johnson, Germany's Zeiss and Bausch in a $9 billion per year market. Rivals in vision care, worth $14 billion annually, include J&J, Cooper and Bausch.


    In 2016, a new Alcon head, Mike Ball from Hospira, redoubled research and marketing spending to resurrect revenue, before Novartis chief Vas Narasimhan decided to shed the division.


    The last comparable-sized Swiss listing was in 2010 when oil driller Transocean floated on the same day its Deepwater Horizon rig exploded in the Gulf of Mexico.


    Read Also: USFDA approves Novartis' oral drug Mayzent to treat multiple sclerosis

    AlconBlackRockJulius BaerNestleNovartisNovartis spinoffRocheSMISwiss benchmarkSwiss Market IndexZuercher KantonalbankZURICH
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok